#NEWS: Novavax announced the U.S. Food and Drug Administration (@FDA) has approved the Company’s Biologics License Application for its COVID-19 vaccine, Nuvaxovid™, triggering a Sanofi milestone payment. Read the news release:

#Statement: Novavax responded to the formal communication request for a postmarketing commitment received from the U.S. Food and Drug Administration (FDA) for our Biologics License Application (BLA). Read more:.

#Statement: We have received formal communication from the U.S. Food and Drug Administration (FDA) about the Novavax COVID-19 vaccine Biologics License Application (BLA). Read more:

At this year’s #ESCMID Congress, we presented new real-world data from the SHIELD-Utah study conducted in partnership with the University of Utah Health. Read more about the findings:

An update on the status of Novavax’s COVID-19 Vaccine BLA

We have a clear corporate growth strategy and many near-term milestones to look forward to in 2025. Read more:

We are focused on driving vaccine innovation to tackle global health challenges and create value for ​.our stakeholders through R&D and additional partnerships. Read more:

Novavax’s corporate growth strategy includes four core value drivers: .🔷 Executing on current partnerships .🔷 Advancing our late-stage pipeline .🔷 Driving additional partnerships and deals through our technology .🔷 Building a robust early-stage pipeline. Learn more:

We are excited to be in San Francisco this week and share how Novavax is executing against our new corporate growth strategy, focused on delivering value through R&D and partnerships. To learn more about how we’re reshaping our future, click here:

We’re excited to be in San Francisco this week having meaningful conversations and sharing our vision for our new corporate growth strategy. Key to this is our  technology platform. When combined with our deep vaccine expertise, it fuels innovation and partnerships that can

We’re excited to share more about our corporate strategy and how we’re focused on harnessing the promise of vaccine innovation to improve global health. Read more about our new approach to R&D and strategic partnerships in this article and our presentation

Our science has been featured in several new publications. Learn more about our research: . #MedicalProfessionals #ScientificCommunity

Novavax’s corporate growth strategy includes efforts to pursue additional partnerships for its late-stage and early-stage Research and Development assets and Matrix-M™ adjuvant alone. This growth strategy should position the Company for ongoing value creation, as additional

Novavax advances its corporate growth strategy through Sanofi partnership with achievement of first $50 million milestone. Read the press release at:

#NEWS: Novavax today announced it has achieved a milestone associated with its Phase 2/3 clinical trial for its #COVID19 vaccine in children, triggering the first $50 million milestone payment from Sanofi. Read the press release:

#NEWS: Novavax initiates its COVID-19-Influenza Combination and stand-alone influenza Phase 3 trial. Read the press release at:

#NEWS: Novavax sells its manufacturing facility in the Czech Republic to Novo Nordisk for $200 million. Read the press release at:

Targeting JN.1, the current "tree trunk," potentially increases the breadth of crossprotection against emerging strains in light of the possibility that future dominant JN.1-descendant strains may not be descendants of KP subvariants. Learn more here:

This week, Novavax is attending the 2024 @Jefferies London Healthcare Conference! . Watch the live webcast here (available for 30 days):

Novavax is excited to attend the @ISPORorg Europe conference in Barcelona, Spain. Our team is looking forward to interesting #HEOR talks focused on improving global public health. Will we see you there?